Vaccinex : Phase I Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab/Trastuzumab in Patients with Metastatic HER2-Positive Breast Cancer (MBC)

(marketscreener.com) SITC 2022 Abstract 645 Phase I Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab/Trastuzumab in Patients with Metastatic HER2-Positive Breast Cancer ...https://www.marketscreener.com/quote/stock/VACCINEX-INC-45256990/news/Vaccinex-Phase-I-Study-of-Adoptive-T-Cell-Therapy-Following-HER2-Pulsed-Dendritic-Cell-Vaccine-and-42271853/?utm_medium=RSS&utm_content=20221110